An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Phase of Trial: Phase I/II
Latest Information Update: 12 Dec 2016
Price : $35 *
At a glance
- Drugs DI Leu16 IL2 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Alopexx Oncology
- 31 Aug 2018 Biomarkers information updated
- 06 Dec 2016 Status changed from recruiting to completed.
- 15 Jan 2015 Planned primary completion date changed to 1 Jul 2017 as reported by ClinicalTrials.gov.